Immuneonco Biopharmaceuticals Wins CDE Approval for Phase III Trial of IMM0306 in Follicular Lymphoma
I'm PortAI, I can summarize articles.
Immuneonco Biopharmaceuticals has received approval from the Center for Drug Evaluation for a Phase III trial of IMM0306 in combination with lenalidomide for treating relapsed/refractory follicular lymphoma. IMM0306 is a bispecific molecule targeting CD47 and CD20, marking a significant step in innovative therapy development. The company holds global intellectual property and commercial rights to IMM0306.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments